Chemical formula: C₁₇H₁₇ClO₆ Molecular mass: 352.766 g/mol PubChem compound: 441140
There are case reports of human foetal abnormalities associated with griseofulvin.
There are no adequate and well controlled studies in man, and inadequate epidemiological data. Griseofulvin has been shown to be teratogenic and embryotoxic in mice and rats.
Griseofulvin is suspected to cause serious birth defects when administered during pregnancy.
Griseofulvin is contraindicated in pregnancy.
Women of childbearing potential have to use effective contraception during (and up to 4 weeks after) treatment in respect of effect on oral contraceptives, and contraceptive precautions.
Griseofulvin has been shown to induce chromosomal aberrations in animal spermatocytes. Therefore men should take effective contraceptive precautions, i.e barrier contraception, to avoid fathering children for the duration of griseofulvin therapy, and for 6 months post therapy cessation.
It is unknown if griseofulvin is excreted in breast milk, but the possibility does exist. There is inadequate data on the safety of griseofulvin in breast feeding, and the potential risk to the infant cannot be assessed, therefore griseofulvin is contraindicated in breast feeding.
Griseofulvin has no or negligible influence on the ability to drive and use machines. However, it may cause drowsiness, confusion dizziness, and impaired co-ordination. Patients should therefore be cautioned not to drive or operate machines until they are sure they are not affected.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
